DK0789588T3 - Metode til fremstilling af et medikament til behandling af sekundær immundefekt - Google Patents

Metode til fremstilling af et medikament til behandling af sekundær immundefekt

Info

Publication number
DK0789588T3
DK0789588T3 DK95942931T DK95942931T DK0789588T3 DK 0789588 T3 DK0789588 T3 DK 0789588T3 DK 95942931 T DK95942931 T DK 95942931T DK 95942931 T DK95942931 T DK 95942931T DK 0789588 T3 DK0789588 T3 DK 0789588T3
Authority
DK
Denmark
Prior art keywords
medicament
preparing
treatment
secondary immunodeficiency
lymphocytes
Prior art date
Application number
DK95942931T
Other languages
Danish (da)
English (en)
Inventor
John W Hadden
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of DK0789588T3 publication Critical patent/DK0789588T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK95942931T 1994-11-17 1995-11-16 Metode til fremstilling af et medikament til behandling af sekundær immundefekt DK0789588T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34164594A 1994-11-17 1994-11-17
PCT/US1995/015492 WO1996015808A1 (en) 1994-11-17 1995-11-16 Method for making a medicament for treating secondary immunodeficiency

Publications (1)

Publication Number Publication Date
DK0789588T3 true DK0789588T3 (da) 2005-05-30

Family

ID=23338440

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95942931T DK0789588T3 (da) 1994-11-17 1995-11-16 Metode til fremstilling af et medikament til behandling af sekundær immundefekt

Country Status (11)

Country Link
US (1) US5698194A (ja)
EP (1) EP0789588B1 (ja)
JP (4) JP4440342B2 (ja)
AT (1) ATE287270T1 (ja)
AU (1) AU694304B2 (ja)
CA (1) CA2205430C (ja)
DE (1) DE69533941T2 (ja)
DK (1) DK0789588T3 (ja)
ES (1) ES2236719T3 (ja)
PT (1) PT789588E (ja)
WO (1) WO1996015808A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3497607B2 (ja) * 1995-05-26 2004-02-16 オリンパス株式会社 接眼光学系及びそれを用いた画像表示装置
US6316257B1 (en) * 1996-03-04 2001-11-13 Targeted Genetics Corporation Modified rapid expansion methods (“modified-REM”) for in vitro propagation of T lymphocytes
DE69810091T2 (de) * 1997-02-21 2003-10-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw., Zwijnaarde Verwendung von interleukin-15
AU748467B2 (en) * 1997-10-17 2002-06-06 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
JP2003511696A (ja) * 1999-10-13 2003-03-25 インサイト・ゲノミックス・インコーポレイテッド 多重的サイトカイン分析
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20020150552A1 (en) * 2000-09-12 2002-10-17 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US6977072B2 (en) 2000-10-27 2005-12-20 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
WO2003035004A2 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20050002899A1 (en) * 2003-07-03 2005-01-06 Eyal Talor Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
EP1691852A2 (en) * 2003-11-10 2006-08-23 Angiotech International AG Medical implants and fibrosis-inducing agents
CN101005760A (zh) * 2004-06-04 2007-07-25 塞尔-赛公司 改变cd4/cd8和进入肿瘤的单核细胞浸润液的方法
ATE513565T1 (de) * 2004-07-30 2011-07-15 Cel Sci Corp Verfahren zum verwalten von cholesterin mit einer serums- und mitogenfreien zytokin-mischung
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture
DK2234642T3 (en) 2007-11-28 2018-01-08 Irx Therapeutics Inc PROCEDURE FOR INCREASING AN IMMUNOLOGICAL EFFECT
US8470562B2 (en) * 2008-04-14 2013-06-25 Irx Therapeutics, Inc. IRX-2 modified manufacturing process
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390623A (en) * 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4448879A (en) * 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
SE8801426D0 (sv) * 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling

Also Published As

Publication number Publication date
JP4440342B2 (ja) 2010-03-24
JP2005245455A (ja) 2005-09-15
EP0789588A1 (en) 1997-08-20
DE69533941T2 (de) 2005-12-29
CA2205430C (en) 2001-09-04
EP0789588B1 (en) 2005-01-19
AU694304B2 (en) 1998-07-16
EP0789588A4 (en) 2001-11-28
PT789588E (pt) 2005-05-31
MX9703626A (es) 1998-12-31
DE69533941D1 (de) 2005-02-24
US5698194A (en) 1997-12-16
ES2236719T3 (es) 2005-07-16
ATE287270T1 (de) 2005-02-15
JP2007236395A (ja) 2007-09-20
AU4411196A (en) 1996-06-17
CA2205430A1 (en) 1996-05-30
WO1996015808A1 (en) 1996-05-30
JPH10510147A (ja) 1998-10-06
JP2009209164A (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
DK0789588T3 (da) Metode til fremstilling af et medikament til behandling af sekundær immundefekt
HUT64595A (en) Method for producing mammalian cytokine, il-11
AU7769887A (en) Apparatus and methods of culturing motile microorganisms
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
AU580494B2 (en) Process for the extraction and purification of proteins from culture media producing them
DK0567586T3 (da) Anvendelse af interleukin-10 ved adoptiv immunterapi af cancer
AU7873187A (en) Method of culturing leukocytes
EP0088195A3 (en) Messenger rna, production and use thereof
CA1267623C (en) CELL CULTURE FILTER APPARATUS AND METHOD OF USE
FI890821A (fi) Menetelmä kudossiirtoon soveltuvien, in vitro-viljeltyjen epiteelikalvojen säilyttämiseksi
AU4277689A (en) Process for producing cultured epidermal sheet, product and method of use
PT73371B (en) A method for enhancing the yield of hepatitis a virus
EP0340783A3 (en) Apparatus for culturing animal cells, method of culturing thereof and diagnostics of the culture
BG49719A3 (en) Method for preparing of variants chirudine and their use
EP0205387A3 (en) Human monocytes cultured in suspension in serum-free medium
ATE268811T1 (de) Therapeutische anwendungen von chimänischer organogenese
AU7913887A (en) Method for the removal of undesired cells from human lymphocyte populations, application of the method in monoclonal antibody production and kit therefor
EP0201800A3 (en) A cholesterol-rich fraction, process therefor and use thereof in cell culture
WO1987007640A1 (en) Process for preparing neuraminidase
Scheicher et al. Recombinant GM-CSF induces in vitro differentiation of dendritic cells from mouse bone marrow
NZ232641A (en) Serum-free tissue culture medium and a method of culturing mammalian cells
EP0299067A4 (en) BREEDING MEDIUM FOR PLANTS.
AU6262786A (en) Growing aids virus in cell lines lacking human class ii histocompatability antigens
GR3031236T3 (en) Process for the preparation of pilocarpine.
DK0485504T3 (da) Fremgangsmåde til fremstilling af aktiveret protein C ved celledyrkning